Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02083510 · ClinicalTrials.gov registry record · Early Phase 1
Apolipoprotein CIII Reduction Via Colchicine
A Early Phase 1 study, sponsored by Scripps Translational Science Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT02083510 is a Early Phase 1 study that has completed, run by Scripps Translational Science Institute. The registered enrollment target is 5 participants.
The verdict
NCT02083510, a Early Phase 1 study, has completed, sponsored by Scripps Translational Science Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The aim of this trial will be to determine an effect-size for the administration of chronic low-dose colchicine in the reduction of serum levels of triglycerides (TG), very-low density lipoproteins (VLDL), and apolipoprotein CIII (apoCIII) in human subjects over a period of 4-6 weeks.
Interventions
- DRUG Colchicine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02083510
The ClinicalTrials.gov registry entry for NCT02083510 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Colchicine is the first listed.
NCT02083510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02083510 about?
NCT02083510 is a clinical study titled "Apolipoprotein CIII Reduction Via Colchicine". The aim of this trial will be to determine an effect-size for the administration of chronic low-dose colchicine in the reduction of serum levels of triglycerides (TG), very-low density lipoproteins (VLDL), and apolipoprotein CIII (apoCIII) in human subjects over a period of 4-6 weeks.
What is the current status of trial NCT02083510?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2014-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02083510?
The interventions under investigation include: Colchicine (DRUG).
Who is sponsoring clinical trial NCT02083510?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.